DellaCamera Capital Management, LLC (“DellaCamera”) and related
entities, which beneficially hold approximately 8.3% of the shares of
Enzon Pharmaceuticals, Inc. (“Enzon” or the “Company”) (NASDAQ: ENZN),
announced today that DellaCamera has been advised by counsel to Enzon
that the Board of Directors has set July 24, 2009 as the record date in
order to determine which Enzon stockholders are entitled to act by
written consent in regards to DellaCamera’s consent solicitation to
amend Enzon’s By-laws and to remove Enzon CEO and President Jeffrey H.
Buchalter.
PLEASE READ THE CONSENT SOLICITATION STATEMENT OF DELLACAMERA CAPITAL
MASTER FUND, LTD. WHEN IT BECOMES AVAILABLE, BECAUSE IT CONTAINS
IMPORTANT INFORMATION INCLUDING INFORMATION ABOUT INDIVIDUALS DEEMED TO
BE PARTICIPANTS IN THE SOLICITATION OF CONSENTS OF ENZON
PHARMACEUTICALS, INC. STOCKHOLDERS. YOU MAY OBTAIN THIS CONSENT
SOLICITATION STATEMENT, OR ANY OTHER RELEVANT DOCUMENTS, FOR FREE AT WWW.SEC.GOV.
YOU MAY ALSO OBTAIN THIS CONSENT SOLICITATION STATEMENT, OR ANY OTHER
INFORMATION RELEVANT TO THE SOLICITATION OF CONSENTS BY DELLACAMERA
CAPITAL MASTER FUND, LTD., BY CONTACTING MACKENZIE PARTNERS, INC., 105
MADISON AVENUE, NEW YORK, NY 10016 AT 800-322-2885. PRESENTLY, A
PRELIMINARY FORM OF THIS CONSENT SOLICITATION STATEMENT IS PUBLICLY
AVAILABLE.
Sard Verbinnen & Co.
Dan Gagnier/Renee Soto, 212-687-8080
